SEE-DRUG’s Major Aim is to strengthen and broaden the scientific reach and socio-economic impact of the University of Patras (UPAT) through the creation of a Regional Centre of Excellence for Structural Biology that emphasizes the characterization and development of bioactive molecules with therapeutic potential.SEE-DRUG takes advantage of UPAT’s pivotal strength and growth potential of Structural Biology and combines it with high-quality, multidisciplinary scientific expertise in Chemistry, Pharmacology, Biology & Bioinformatics. The SEE-DRUG project will enable: (a) the Protein Production group to efficiently produce and characterize protein drug-targets for structural analysis and drug development efforts, (b) the Structural Biology group to perform high-resolution structure determination, through time- and cost-effective NMR-based, cutting-edge techniques, and (c) the Pharmacology group to characterize lead therapeutic molecules in a comprehensive array of in vitro, ex vivo and in vivo systems.The long-term benefits of SEE-DRUG implementation will manifest on 3 levels: (a) the pooling of scientific expertise & the upgrading of infrastructure within UPAT, (b) the optimal integration of UPAT’s Structural Biology in ERA through the establishment of long-lasting partnerships, (c) the creation of a solid scientific platform that will become a pole for therapeutic biomolecule-oriented Structural Biology in Greece and in SouthEastern EU, and (d) the exchange of expertise (via twinning actions with 8 EU partnering organizations) and the building of networks with other scientists and technology end-users at a regional or local level, including the bio-pharmaceutical industry. Last, but not least, such a state-of-the-art Centre will create a number of positions for highly skilled scientists and thus enhance scientific and economic growth both at a local and at a regional level, which will hopefully be sustained for years to come.